Back to search

Article

Analysis of Copy Number Loss of the ErbB4 Receptor Tyrosine Kinase in Glioblastoma

2017-06-23

Abstract excerpt

<h4>ABSTRACT</h4> Current treatments for glioblastoma multiforme (GBM)—an aggressive form of brain cancer—are minimally effective and yield a median survival of 14.6 months and a two-year survival rate of 30%. Given the severity of GBM and the limitations of its treatment, there is a need for the discovery of novel drug targets for GBM and more personalized treatment approaches based on the characteristics of an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d2eb516e-60da-5421-be60-5daf5b645f4e
DOI
10.1101/154815
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Analysis of Copy Number Loss of the ErbB4 Receptor Tyrosine Kinase in GlioblastomaDOI 10.1101/154815
Select a neighboring publication to make it the new centre.